Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients

OBJECTIVES: To evaluate the efficacy and safety of cabozantinib, through a bridging study to METEOR, in Japanese patients with advanced renal cell carcinoma who had progressed after prior tyrosine kinase inhibitor therapy. METHODS: This phase II, open‐label, single‐arm study (ClinicalTrials.gov regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Tatsugami, Katsunori, Nakaigawa, Noboru, Osawa, Takahiro, Oya, Mototsugu, Kanayama, Hiroomi, Nakayama Kondoh, Chihiro, Sassa, Naoto, Nishimura, Kazuo, Nozawa, Masahiro, Masumori, Naoya, Miyoshi, Yasuhide, Kuroda, Shingo, Tanaka, Shingo, Kimura, Akiko, Tamada, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles: Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689847/
https://www.ncbi.nlm.nih.gov/pubmed/32789967
http://dx.doi.org/10.1111/iju.14329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689847/
https://www.ncbi.nlm.nih.gov/pubmed/32789967
http://dx.doi.org/10.1111/iju.14329

Ejemplares similares